Shots:
- Telix has dosed the first patient with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the P-III (LUTEON) study to identify eligible pts with CAIX-positive tumors in r/r clear cell renal cell carcinoma (ccRCC)
- LUTEON trial in Australia is part of Telix’s global development program for TLX250-Tx, alongside the P-IIa (LUTEON ATLAS) study in the US & EU
- TLX250-Tx is a first-in-class CAIX-targeting radiopharmaceutical drug conjugate (rADC) that combines a highly specific monoclonal antibody with the therapeutic radionuclide lutetium-177
Ref: Globenewswire | Image: Telix | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
